News archive search
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
Active search
Search results
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
The Basic Materials group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Has Aperam (APEMY) been one of those stocks this year? By taking a look at the stock's year-to-date performance in comparison to …
Sharemaestro market context Trend signal active 52 weeks +86.0% · Next-week setup positive 59.4%The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price. Do they really matter, though? Before …
Sharemaestro market context Trend signal active 52 weeks +30.6% · Next-week setup negative 30.7%Stifel has reiterated its Buy rating and $114.00 price target for Veralto Corp. (NYSE:VLTO) after the company announced its acquisition of Cleanwater1 for $465 million. The acquisition, valued at 17 times Cleanwater1’s last twelve months adjusted EBITDA, is expected to close in Q4 2026. …
Travere Therapeutics (TVTX) saw its stock rise by 6.1% following news that its drug FILSPARI's launch for FSGS is exceeding expectations, driven by strong physician demand. This success reinforces the company's kidney-focused portfolio, which also includes a Phase III trial for pegtibatinase and the …
HC Wainwright & Co. has maintained a "Buy" rating for Relay Therapeutics (RLAY) and raised its price target to $29, reflecting cautious optimism despite the company's financial challenges. However, GuruFocus's GF Value™ indicates RLAY is significantly overvalued by 493.4%, and its GF Score™ of …
Underground water, sewer and utility lines can create costly problems with little warning LOS ANGELES, Aug. 20, 2026 /PRNewswire/ -- Some of the most important parts of a home are the ones homeowners rarely see. Mercury Insurance (NYSE/NYSE TX: MCY) is reminding homeowners that …
General Mills has launched a new limited-edition Reese's Puffs PB+J cereal, blending the signature peanut butter and chocolate flavors with strawberry jelly. This nostalgic offering follows the success of Reese's PB+J Cups and Reese's Puffs Dark Chocolate cereal. The cereal is available nationwide for …
Amgen has terminated its research collaboration and license agreement with TScan Therapeutics, effectively removing over $500 million in potential milestone payments for TScan. The agreement, originally signed in May 2023, focused on using TScan's platform to identify antigens for Crohn's disease, with Amgen holding …
Rein Therapeutics has been granted Fast Track designation by the FDA for its idiopathic pulmonary fibrosis (IPF) drug, LTI-03. This designation aims to accelerate the development and review process for LTI-03, an inhaled peptide therapy designed to inhibit lung scarring. The company is currently …
Rein Therapeutics has been granted FDA Fast Track designation for LTI-03, its drug for idiopathic pulmonary fibrosis (IPF), which will expedite its development and review. LTI-03 is a novel inhaled peptide therapy designed to slow lung scarring and promote healing, currently in a Phase …
Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St. Generac Holdings has delivered an 84.8% gain over the past three years, yet the valuation picture is mixed, with the intrinsic value estimate from …
This page provides a comprehensive resource for WhiteHawk Minerals Corp. (WHK) SEC filings, including 10-K, 10-Q, 8-K forms, and insider trading disclosures. Each filing is accompanied by expert analysis from Rhea-AI, offering insights into potential market impact, sentiment scores, and end-of-day stock performance data. …
This article analyzes Allogene Therapeutics (NASDAQ:ALLO) and suggests it is in a strong financial position to invest in growth. It likely reviews the company's financial health, market performance, or strategic advantages that enable such investments. The analysis indicates a positive outlook regarding the company's …
HC Wainwright has increased its price target for Relay Therapeutics (NASDAQ:RLAY) to $29 from $28, maintaining a "buy" rating and projecting a 39.8% upside. Despite a recent quarterly loss of $0.41 per share and revenue below estimates, analyst sentiment remains largely positive, with a …
H.C. Wainwright has reiterated a Buy rating for Seaport Therapeutics (NASDAQ:SPTX) with a $50.00 price target. The firm highlighted that the positive clinical data from a competitor's candidate could reduce competitive pressure for Seaport's GlyphAllo, and their non-hallucinogenic psychedelic candidate, Glyph2BLSD, could offer a …
HC Wainwright has reaffirmed its "Buy" rating for Seaport Therapeutics (SPTX), setting a $50 price target, which suggests a 104.75% upside. Despite this, analyst sentiment remains mixed, leading to a consensus "Hold" rating with an average target of $38.40. The company recently reported a …
Search by ticker symbol or company name and select a result to open its chart. The US only control limits results to active US-listed stocks and ETFs.
Showing active US-listed stocks and ETFs only.